{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:27Z","timestamp":1793212107089,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bronchial asthma (asthma) is a chronic inflammatory disease of the airways, involving a variety of cells and cellular components, that manifests clinically as recurrent episodes of wheezing, shortness of breath, with or without chest tightness or cough, airway hyperresponsiveness, and variable airflow limitation. The number of people with asthma has reached 358 million worldwide and asthma causes huge economic loss. However, there is a subset of patients who are not sensitive to existing drugs and the existing drugs have many adverse effects. Therefore, it\u2019s important to find new drugs for asthma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications related to biologics in asthma published from 2000 to 2022 were retrieved from Web of Science Core Collection. The search strategies were as follows: topic: TS=(biologic* OR \u201cbiologic* product*\u201d OR \u201cbiologic* therap*\u201d OR biotherapy* OR \u201cbiologic* agent*\u201d OR Benralizumab OR \u201cMEDI-563\u201d OR Fasenra OR \u201cBIW-8405\u201d OR Dupilumab OR SAR231893 OR \u201cSAR-231893\u201d OR Dupixent OR REGN668 OR \u201cREGN-668\u201d OR Mepolizumab OR Bosatria OR \u201cSB-240563\u201d OR SB240563 OR Nucala OR Omalizumab OR Xolair OR Reslizumab OR \u201cSCH-55700\u201d OR SCH55700 OR \u201cCEP-38072\u201d OR CEP38072 OR Cinqair OR \u201cDCP-835\u201d OR DCP835 OR Tezspire OR \u201ctezepelumab-ekko\u201d OR \u201cAMG-157\u201d OR tezspire OR \u201cMEDI-9929\u201d OR \u201cMEDI-19929\u201d OR MEDI9929 OR Itepekimab OR \u201cREGN-3500\u201dOR REGN3500 OR \u201cSAR-440340\u201dOR SAR440340 OR Tralokinumab OR \u201cCAT-354\u201d OR Anrukinzumab OR \u201cIMA-638\u201d OR Lebrikizumab OR \u201cRO-5490255\u201dOR \u201cRG-3637\u201dOR \u201cTNX-650\u201dOR \u201cMILR1444A\u201dOR \u201cMILR-1444A\u201dOR\u201dPRO301444\u201dOR \u201cPRO-301444\u201dOR Pitrakinra OR altrakincept OR \u201cAMG-317\u201dOR\u201dAMG317\u201d OR Etokimab OR Pascolizumab OR \u201cIMA-026\u201dOR Enokizumab OR \u201cMEDI-528\u201dOR \u201c7F3COM-2H2\u201d OR 7F3COM2H2 OR Brodalumab OR \u201cKHK-4827\u201d OR \u201cKHK4827\u201dOR \u201cAMG-827\u201dOR Siliq OR Ligelizumab OR \u201cQGE-031\u201d OR QGE031 OR Quilizumab OR Talizumab OR \u201cTNX-901\u201d OR TNX901 OR Infliximab OR Etanercept OR \u201cPRS-060\u201d) AND TS=asthma*. The document type was set to articles and review articles and the language restriction was set to English. Three different analysis tools including one online platform, VOS viewer1.6.18, and CiteSpace V 6.1.R1 software were used to conduct this bibliometric  study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This bibliometric  study included 1,267 English papers published in 244 journals from 2,012 institutions in 69 countries\/regions. Omalizumab, benralizumab, mepolizumab, and tezepelumab in relation to asthma were the research hotspots in the field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study systematically uncovers a holistic picture of existing literature related to the biologic treatment of asthma over the past 20 years. We consulted scholars in order to understand key information in this field from the perspective of bibliometrics, which we believe may greatly facilitate future research in this field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1034755","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T06:08:13Z","timestamp":1675922893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiamin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112147-20200618-00721","article-title":"Asthma group of Chinese Throacic Society. Guidelines for bronchial asthma prevent and management. Asthma group of Chinese Throacic Society","volume":"43","year":"2020","journal-title":"Chin J Tuberculosis Respir Diseases."},{"key":"B2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5415\/apallergy.2014.4.2.75","article-title":"Epidemiology of adult asthma in Asia: toward a better understanding","volume":"4","author":"Song","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global initiative for asthma strategy 2021: Executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.12616","article-title":"EAACI IG biologicals task force paper on the use of biologic agents in allergic disorders","volume":"70","author":"Boyman","year":"2015","journal-title":"Allergy."},{"key":"B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","article-title":"DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: An overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J Business Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"Eck","year":"2010","journal-title":"Scientometrics."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953465","article-title":"Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: A bibliometric analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731933","article-title":"A bibliometric analysis of pyroptosis from 2001 to 2021","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/asi.22968","article-title":"Patterns of connections and movements in dual-map overlays: A new method of publication portfolio analysis","volume":"65","author":"Chen","year":"2014","journal-title":"J Assn Inf Sci Tec"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1025618","article-title":"Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"(omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2307\/3033543","article-title":"A set of measures of centrality based on betweenness","volume":"40","author":"Freeman","year":"1977","journal-title":"Sociometry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0378-8733(78)90021-7","article-title":"Centrality in social networks conceptual clarification","volume":"1","author":"Freeman","year":"1978","journal-title":"Soc Networks"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1753466618810192","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: A meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u201dReal-life\u201c effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy."},{"key":"B25","unstructured":"2022 GINA main report - global initiative for asthma - GINA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13601-020-00330-1","article-title":"Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis","volume":"10","author":"Heffler","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: A real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: The REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2100396","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.08.013","article-title":"Safety of biologics for atopic diseases during pregnancy","volume":"10","author":"Shakuntulla","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: A potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-020-01503-z","article-title":"SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"21","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1630817","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1034755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:22:20Z","timestamp":1751955740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1034755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2023.1034755"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1034755","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"article-number":"1034755"}}